Eudaimonia Partners’s Quest Diagnostics DGX Stock Holding History

Eudaimonia Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$337K	Hold	2,535	–	–	0.08%	186
2023 Q4	$350K	Hold	2,535	–	–	0.09%	169
2023 Q3	$309K	Hold	2,535	–	–	0.07%	226
2023 Q2	$356K	Sell	2,535 -3	-0.1%	-$414	0.08%	232
2023 Q1	$359K	Buy	2,538 +3	+0.1%	+$429	0.09%	232
2022 Q4	$397K	Hold	2,535	–	–	0.1%	204
2022 Q3	$311K	Sell	2,535 -60	-2%	-$7.9K	0.08%	239
2022 Q2	$345K	Sell	2,595 -71	-3%	-$9.68K	0.06%	273
2022 Q1	$365K	Buy	+2,666	New	+$372K	0.06%	289
2021 Q3	$458K	Sell	3,154 -294	-9%	-$43K	0.08%	240
2021 Q2	$455K	Buy	3,448 +230	+7%	+$30.1K	0.09%	239
2021 Q1	$413K	Hold	3,218	–	–	0.09%	223
2020 Q4	$383K	Sell	3,218 -9	-0.3%	-$1.1K	0.09%	223
2020 Q3	$369K	Buy	3,227 +116	+4%	+$13.7K	0.1%	206
2020 Q2	$355K	Sell	3,111 -26	-0.8%	-$2.76K	0.13%	169
2020 Q1	$252K	Sell	3,137 -6	-0.2%	-$621	0.11%	186
2019 Q4	$336K	Buy	+3,143	New	+$328K	0.13%	173

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eudaimonia Partners's DGX Position: Q1 2024 in Review

Eudaimonia Partners held its Quest Diagnostics (DGX) position steady in Q1 2024 at 2,535 shares worth $337K. The position accounts for 0.08% of the portfolio, ranked #186.

Eudaimonia Partners first reported a position in DGX in Q4 2019 and has held it in 17 quarters since. The position peaked at $458K in Q3 2021. 818 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

Eudaimonia Partners held 2,535 shares of Quest Diagnostics worth $337K as of Q1 2024.
Eudaimonia Partners left its Quest Diagnostics share count unchanged in Q1 2024.
Quest Diagnostics made up 0.08% of Eudaimonia Partners's portfolio in Q1 2024, its #186 holding.
Eudaimonia Partners first reported a position in Quest Diagnostics in Q4 2019 and has held it in 17 quarters since.
Eudaimonia Partners's Quest Diagnostics position peaked at $458K in Q3 2021.
818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.